Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma
1 other identifier
interventional
17
1 country
1
Brief Summary
Control of airway inflammation is the cornerstone of asthma management. The aim of the present pilot study was to assess whether, and in which magnitude, a leukotriene receptor antagonist (LTRA) added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) might improve airway hyperresponsiveness and inflammation in well-controlled patients with asthma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4 asthma
Started Jan 2007
Longer than P75 for phase_4 asthma
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2012
CompletedFirst Submitted
Initial submission to the registry
November 8, 2012
CompletedFirst Posted
Study publicly available on registry
November 12, 2012
CompletedAugust 7, 2017
August 1, 2017
4.9 years
November 8, 2012
August 4, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
pd15 mannitol
Improvement in pd15 mannitol over a treatment period of 4 weeks.
4 weeks
Secondary Outcomes (1)
pd20 methacholine
4 weeks
Other Outcomes (2)
Juniper asthma control questionnaire
4 weeks
exhaled nitric oxide
4 weeks
Study Arms (1)
montelukast
EXPERIMENTALA leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
Interventions
Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
Eligibility Criteria
You may qualify if:
- clinically well-controlled asthma
You may not qualify if:
- Smokers
- women planning a pregnancy or pregnant
- patients with any significant illness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Bern
Bern, CH-3010, Switzerland
Related Publications (1)
Kononowa N, Michel S, Miedinger D, Pichler CE, Chhajed PN, Helbling A, Leuppi JD. Effects of add-on montelukast on airway hyperresponsiveness in patients with well-controlled asthma - a pilot study. J Drug Assess. 2013 Apr 2;2(1):49-57. doi: 10.3109/21556660.2013.791300. eCollection 2013.
PMID: 27536437DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Arthur Helbling, MD
University Hospital Bern Switzerland
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr.
Study Record Dates
First Submitted
November 8, 2012
First Posted
November 12, 2012
Study Start
January 1, 2007
Primary Completion
December 1, 2011
Study Completion
January 1, 2012
Last Updated
August 7, 2017
Record last verified: 2017-08